Physician profile
Jacob Standard
NPI 1730703364
$1,128.05
in general payments reported to CMS, 2019-2025
23 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.30 · 2023: $136 · 2024: $652 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $212.86 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $155.91 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $153.61 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $93.09 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $62.22 | 2021-2025 | |
| Spr Therapeutics, INC | $50.51 | 2024 | Sprint Pns System |
| Philips North America LLC | $42.17 | 2024 | (Ck7) Extended Holter |
| Amgen INC. | $41.34 | 2024 | Repatha, Otezla |
| Astellas Pharma US INC | $39.17 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.47 | 2023-2025 | Jardiance |
| Itamar Medical INC | $26.40 | 2024 | Watchpatone |
| Pfizer INC. | $24.78 | 2024 | |
| Merck Sharp & Dohme LLC | $23.29 | 2024 | Vaqta, Gardasil 9, Recombivax Hb |
| Acella Pharmaceuticals, LLC | $22.83 | 2024 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $21.47 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $20.52 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $18.45 | 2025 | Arexvy, Bexsero, Shingrix |
| Lundbeck LLC | $15.93 | 2023 | Vyepti |
| Tolmar, INC. | $15.85 | 2024 | |
| Cranial Technologies, INC | $15.72 | 2025 | Doc Band |
| Angiodynamics, INC. | $14.65 | 2025 | Smart Port Ct |
| Currax Pharmaceuticals LLC | $13.66 | 2023 | Onzetra Xsail, Nexletol, Nexlizet |
| Idorsia Pharmaceuticals US INC | $13.15 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Standard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.